K

Kytopen

42 employees

Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Life Science
Mechanical engineering
Drug Discovery
Cas9
CAR T-cell
T cells
Immunotherapy
Transfection
Cell engineering
Genetics
Manufacturing
Gene Therapy
CD34+ stem cells
Nonviral
Gene Editing
Cell Therapy
Health Care
RNP delivery
Stem Cells
Immunology
mRNA
Genetic engineering
CRISPR
NK cells
Mammalian cells

Date founded

2017

Funding rounds raised

Total raised

$30M

from 12 investors over 12 rounds

K

Kytopen raised $30M on September 28, 2021

Investors: The Engine, TBD Angels, Northpond Ventures and MassVentures

K

Kytopen raised $2M on June 16, 2021

Investors: National Institute of Allergy and Infectious Diseases (NIAID)

K

Kytopen raised $195K on December 8, 2020

Investors: TBD Angels

K

Kytopen raised $300K on October 26, 2020

Investors: MassVentures

K

Kytopen raised $3.6M on May 28, 2019

Investors: The Engine and Horizons Ventures

K

Kytopen raised undisclosed on June 27, 2018

Investors: MassVentures and Massachusetts Clean Energy Center

K

Kytopen raised undisclosed on September 19, 2017

Investors: The Engine

FAQ